Menu Close

Interdisciplinary panel offers solutions to improve recruitment for Alzheimer’s clinical trials

Unless cures are found, Alzheimer’s dementia is projected to affect nearly 13 million Americans by 2050—overwhelming families, caregivers and our healthcare system. Yet only one new therapeutic, aducanumab, has come to market in the past 20 years, and therapeutic progress remains hampered for several reasons: recruiting study participants in clinical trials for Alzheimer’s is more challenging than other disease areas, the trials take longer to complete and they are more costly. A significant increase in the number of qualified volunteers from diverse backgrounds will be needed in the coming years for clinical trials for Alzheimer’s to be successful.

Generated by Feedzy